scholarly journals Differences in platelet aggregation in coronary sinus and aortic blood in patients with coronary artery disease: Effect of propranolol

1978 ◽  
Vol 1 (2) ◽  
pp. 96-100 ◽  
Author(s):  
J. Mehta ◽  
P. Mehta ◽  
C. J. Pepine ◽  
C. Burger
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Platelet Aggregation ◽  
Coronary Sinus ◽  
Aortic Blood ◽  
Artery Disease ◽  
Disease Effect

Thrombopoietin and platelet aggregation in patients with stable coronary artery disease

Platelets ◽  
2017 ◽  
Vol 28 (8) ◽  
pp. 822-824
Author(s):  
Sanne Bøjet Larsen ◽  
Erik Lerkevang Grove ◽  
Søs Neergaard-Petersen ◽  
Morten Würtz ◽  
Anne-Mette Hvas ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Platelet Aggregation ◽  
Stable Coronary Artery Disease ◽  
Artery Disease

Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: Effect of statins on let-7i and Toll-like receptor 4 signal

Immunobiology ◽  
2012 ◽  
Vol 217 (5) ◽  
pp. 533-539 ◽  
Author(s):  
Mamoru Satoh ◽  
Tsuyoshi Tabuchi ◽  
Yoshitaka Minami ◽  
Yuji Takahashi ◽  
Tomonori Itoh ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Artery Disease ◽  
Disease Effect

Accelerated coronary artery disease after heart transplantation: the role of enhanced platelet aggregation and thrombosis

1993 ◽  
Vol 233 (4) ◽  
pp. 343-350 ◽  
Author(s):  
M. LORGERIL ◽  
R. LOIRE ◽  
J. GUIDOLLET ◽  
P. BOISSONNAT ◽  
G. DUREAU ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Platelet Aggregation ◽  
Heart Transplantation ◽  
Artery Disease

scholarly journals Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease

TH Open ◽  
2021 ◽  
Vol 05 (03) ◽  
pp. e230-e238
Author(s):  
Oliver Buchhave Pedersen ◽  
Anne-Mette Hvas ◽  
Hans Beier Ommen ◽  
Steen Dalby Kristensen ◽  
Erik Lerkevang Grove
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Platelet Aggregation ◽  
Essential Thrombocythemia ◽  
Antiplatelet Effect ◽  
Immature Platelet Fraction ◽  
Increased Risk ◽  
Platelet Disorder ◽  
Patient Groups ◽  
Artery Disease

Abstract Background Patients with essential thrombocythemia (ET) and coronary artery disease (CAD) have increased risk of thromboembolic complications. In addition, a reduced antiplatelet effect of aspirin has been demonstrated in both patient groups. As ET is a platelet disorder, platelets may be more important for the thromboembolic risk in ET than in CAD. We aimed to investigate the antiplatelet effect of aspirin and platelet turnover in ET versus CAD patients. Methods We included 48 ET patients and an age-matched group of 48 CAD patients. The effect of aspirin was evaluated by thromboxane B2 (TXB2) levels and platelet aggregation. Platelet turnover was assessed by immature platelet count (IPC) and immature platelet fraction (IPF). Results ET patients had reduced effect of aspirin compared with CAD patients, demonstrated by significantly higher TXB2 levels (median of differences = 22.3 ng/mL, p < 0.0001) and platelet aggregation (median of differences = 131.0 AU*min, p = 0.0003). Furthermore, ET patients had significantly higher IPC (p < 0.0001) and IPF (p = 0.0004) than CAD patients. Conclusion ET patients have lower 24-hour antiplatelet effect of aspirin than CAD patients. This may be explained by an increased platelet production and turnover counteracting the antiplatelet effect of aspirin. These findings strengthen the rationale for exploring novel antiplatelet regimens in ET patients to reduce the risk of cardiovascular events.

Sign in / Sign up

Export Citation Format

Share Document